Patients on Opioid Substitution Treatment in the Republic of Macedonia: What Do Treatment Demand Data Tell Us? by Petrushevska, Tatjana & Velik Stefanovska, Vesna
 _______________________________________________________________________________________________________________________________ 
OA Maced J Med Sci. 2014 Jun 15; 2(2):335-343.                                                                                                                                                                         335 
 
Open Access Macedonian Journal of Medical Sciences. 2014 Jun 15; 2(2):335-343. 
http://dx.doi.org/10.3889/oamjms.2014.058 
Public Health 
 
 
Patients on Opioid Substitution Treatment in the Republic of 
Macedonia: What Do Treatment Demand Data Tell Us? 
 
 
Tatjana Petrushevska
1*
, Vesna Velik Stefanovska
2
 
   
1
Ministry of Health of the Republic of Macedonia, Skopje, Republic of Macedonia; 
2
Institute for Epidemiology and Medical 
Biostatistics, Medical Faculty, Ss. Cyril and Methodius University of Skopje, Skopje, Republic of Macedonia 
 
 
 
 
Citation: Petrushevska T, Velik Stefanovska V. 
Patients on Opioid Substitution Treatment in the 
Republic of Macedonia: What Do Treatment 
Demand Data Tell Us? OA Maced J Med Sci. 
2014 Jun 15; 2(2):335-343. 
http://dx.doi.org/10.3889/oamjms.2014.058 
Key words: OST; patient demographic 
characteristics; poly drug use; living status; 
heroin use; MMT. 
*
Correspondence: Dr. Tatjana Petrushevska. 
Ministry of Health, "Vodnjanska" bb, Skopje 
1000, Republic of Macedonia. E-Mail: 
tanja.petrusevska@gmail.com 
Received: 27-Feb-2014; Revised: 07-May-
2014; Accepted: 10-May-2014; Online first: 
28-May-2014 
Copyright: © 2014 Petrushevska & Velik 
Stefanovska. This is an open access article 
distributed under the terms of the Creative 
Commons Attribution License, which permits 
unrestricted use, distribution, and reproduction 
in any medium, provided the original author 
and source are credited. 
Competing Interests: The authors have 
declared that no competing interests exist. 
 
 
 
 
 
 
Abstract  
AIM: The aim of the survey is to analyze national data from opioid substitution treatment (OST) 
medical records and to compare it with the data from EU countries. 
MATERIAL AND METHODS: The survey is quantitative analytical cross-sectional study conducted 
in the period September - December 2013. Medical records from all patients on OST at national 
level during the year 2012 were analyzed. EMCDDA questionnaire from treatment protocol 3.0 was 
used. Data for OST patients on MMT was take from all 12 public treatment facilities, three private 
centers and 3 prisons. Data for OST patients on buprenorphine was taken from public clinic as the 
only one responsible for this type of treatment. 
RESULTS: A comprehensive network, diverse models of treatment intervention exists in the MKD. 
Total number of OST patients in 2012 in all treatment facilities was 1857 (1356 are in public, 141 in 
private, 360 in prison settings) 10% are on Buprenorphine and 90% are on Methadone, 52% in age 
group 20-34. Ratio of male to female heroin clients is 9:1; 162 are female (9 %); 107(66%) are in 
treatment in the age group 20-34. Average number of OST patients is 0.1% of the total population 
in each of the 10 cities analyzed. The mean age at first heroin use is 18 years. 40% of patients 
haven’t high school. With their family lives 65% of OST patients; 487 patients (36%) have children; 
80% of patients use of benzodiazepines. 
CONCLUSION: Although treatment network of drug addiction is quite developed, perceived need 
for further capacity building and increase the quality of medical care implies increasing the 
availability, diversification in terms of sensitivity to cultural differences, gender, age, ethnicity, as 
well as the treatment of dependence of different types of psychoactive substances. 
  
 
 
 
Introduction 
The majority of Afghan heroin trafficked into 
Western and Central Europe comes through the 
Balkan route. Of the 75-80 tons of heroin trafficked to 
Western and Central Europe in 2009, some 60 tons 
were estimated to have been trafficked from countries 
of South Eastern Europe (via the Balkan route) [1]. 
The so-called “Balkan Route” has been used for illicit 
trafficking since the seventh century as it is the 
shortest road from the East to Western Europe. The 
route starts in Afghanistan via Turkey and Macedonia, 
to Western EU countries as final destination [2]. 
Narcotics, predominantly heroin, are clear and present 
danger in Macedonia. 
Problem drug use is defined as “injecting drug 
use or long-duration/regular use of opioids, cocaine 
and/or amphetamines” [3]. The current number of 
problem opioid users in Europe can be estimated at 
about 1.4 million, or 0.41 % of the adult population, 
with heroin being by far the most widely used opioid 
[4]. Opiate dependence is a chronic relapsing 
condition with sometimes catastrophic effects for 
individuals, families and communities [5]. It is 
relapsing brain disease characterized by compulsive 
drug-seeking and use despite harmful consequences 
and by long-lasting structural and functional changes 
in the brain [6], which is chronic [7], relapsing [8], 
progressive, compulsive [9]. 
Care of IDUs (intravenous drug users) 
requires interdisciplinary treatment of drug addiction 
and its psychosocial and somatic complications [10]. 
There are different treatment modalities available in 
different countries and studies have shown that 
treatment interventions can have great benefits. It is 
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estimated that approximately one in six problem drug 
users globally receives treatment for drug use 
disorders or dependence each year. However, there is 
a great variation and wide disparity in the availability 
and accessibility of drug dependance treatment 
services in different regions [11]. 
Opioid substitution therapy supplies illicit drug 
users with a replacement drug, a prescribed medicine 
such as methadone or buprenorphine, which is 
usually administered orally in a supervised clinical 
setting [12]. Substitution treatment contributes to the 
stabilization of opiate users living situation; it is a long-
term intervention with the goal of reducing or 
eliminating the use of an illicit opioid drug, or to 
reduce harm and dangers for health, HIV risk 
behaviors, death from overdose and criminal activity, 
and financial and other stresses on drug users and 
their families [13-15]. Conducted a meta-analytic 
review of cognitive behavioral therapy for drug abuse 
and dependence including 34 randomized controlled 
trials (with 2,340 patients treated), larger treatment 
effect sizes were found for treatment of cannabis, 
followed by treatments for cocaine, opioids, and, with 
the smallest effect sizes, poly-substance dependence 
[16].  
Medication-assisted treatment using 
methadone is one of the most efficacious treatments 
for opiate addiction [17-18]. Effectiveness of MMT 
(methadone maintenance treatment) was consistent 
across culturally diverse settings, between developed 
and developing countries [19]. Methadone, a complete 
opioid agonist, approved as a treatment for heroin 
addiction, can help to reduce heroin use, alleviate 
withdrawal symptoms, and consequently improve 
overall health and social relationships. Heroin users 
taking methadone should be able to improve cognitive 
functions and return to normal daily activities [20], 
they can function normally, to overcome their 
psychological problems and dependence on illicit 
opiates. Methadone supports them in achieving 
certain life goals. Dependence on methadone and the 
drug's paralyzing effects on their emotions were 
mentioned as common negative consequences [21]. 
Opioid substitution therapy is not a cure for 
drug dependence – it is a therapy for management of 
a chronic condition [22]. Low retention and drug 
abstinence rates remain a primary problem in treating 
addiction [23]. Substantial relapse and drop-out rates 
in MMT cohorts have been observed in various 
settings, due to multiple causes, including patient’s 
attributes, therapeutic process, environmental 
influences and program characteristics [24-27]. 
Methadone is highly effective in treating opioid 
dependence; it is also used as an analgesic for 
second-line management of chronic pain. Patients 
enrolled in a methadone maintenance treatment 
program may become physically dependent and may 
experience methadone withdrawal symptoms [28]. 
Opioid overdose was the main cause of the estimated 
99,000-253,000 deaths worldwide related to illicit drug 
use in 2010 [29]. Opioid overdose rates [30] are 
associated with: an increased availability of opioids, 
both illicit and prescribed; combination of opioids and 
other psychoactive substances especially sedating 
psychoactive substances, (predominantly alcohol and 
benzodiazepines); a lack of treatment; reduced 
tolerance due to a recent period of abstinence. 
Treatment of opioid dependence with opioid agonist 
maintenance treatment (also known as “opioid 
substitution treatment”) reduces opioid overdose risk 
by almost 90 per cent [31]. 
Treatment data provide results on two levels: 
a direct measurement of the demand on treatment 
services and an indirect measurement of trends in 
drug use [32]. 
Treatment Demand Data (TDI) data are now 
routinely used in the European Monitoring Centre for 
Drugs and Drug Addiction (EMCDDA), analyses of the 
drug situation in Europe, it is widely recognized as the 
instrument for collecting and reporting data on people 
entering treatment for their drug use. Drug treatment 
centers represent a fundamental information source to 
gain insight into problem drug use, which is difficult to 
quantify and describe, but not all problem drug users 
are in contact with treatment, (e.g. some are socially 
integrated cocaine or cannabis users, some very 
marginalized heroin users) or they could be in contact 
with services that, for different reasons, may not 
collect information from their clients, or do not report it 
to national monitoring systems. However, in many EU 
countries the TDI reports information from a 
considerable number of problem drug users (in some 
cases over 50 % of the overall estimated number of 
PDUs). Trends observed in the TDI can signal 
important developments in problem drug use (e.g. 
changes in injection behaviour, expansion of use, etc.) 
and data obtained through the TDI it is an essential 
component prevalence of problem drug use.   
The aim of the survey is to analyze national 
data from OST medical records and to compare it with 
the data from EU countries.  
 
Material and Methods  
The survey in this paper is quantitative 
analytical cross-sectional study conducted in the 
period September-December 2013. Medical records 
from all patients on OST at national level during the 
year 2012 were analyzed. Data was collected with the 
support of responsible physicians and with respect of 
confidentiality of the patients. Data for OST patients 
on MMT was take from all 13 public treatment facilities 
located in the 10 cities (Skopje, Strumica, Kumanovo, 
Stip, Ohrid, Gevgelija, Bitola, Veles, Kavadarci and 
Tetovo), 3 private centers located in the capital of 
Skopje, and 3 prisons. Data for OST patients on 
buprenorphine was taken from Clinic for Toxicology, 
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Clinical Center “Mother Thereza”, University ”St. Cyril 
and Methodius” Skopje. 
The data collected for Macedonia was 
compared with data from 10 EU countries (Austria, 
Denmark, France, Germany, Greece, Italy, Norway, 
Portugal, Sweden, UK).  
 
Questionnaire  
For this paper standardized questionnaire, 
Treatment demand indicator (TDI) - Protocol. 3.0 from 
EMCDDA [33] were used. The first part of the 
questionnaire is related to the socio-demographic 
characteristics as: a) gender, b) age, c) living status 
(with whom), d) ethnicity, e) drug clients with children, 
f) living status (where), g) labor status, h) level of 
education. Second part of the questionnaire was 
related to poly drug use with focus on 
benzodiazepines use (secondary drugs).  
Statistical analysis 
Descriptive statistics was applied for analyze 
of data. Excel and Statistics for Windows 7.0 was 
used. The results were presented in tables.  
 
Results  
Socio-demographic characteristics  
Macedonian legislation set up inclusion 
criteria for MMT - 18 year of age and above. In special 
circumstances, younger persons can be included in 
MMT. In the analyzed period 5 persons were on 
treatment in the age category 15-19, 1 per MMT in 
public and private centers and 3 in prisons. With those 
total No of OST patients are 1,671.
 
Table 1: OST patients on methadone maintenance treatment.   
 
20-34 35-40 41-55 Total % 
M F Total M F Total M F Total   
  Public centers 
No 510 63 573 353 50 403 176 17 193 1169 70% 
% 43.6 5.4 49 30 4 34.5 15 1.5 16.5 100%  
  Private centers 
No 94 15 109 15 3 18 11 2 13 140 8.4% 
% 67 11 77 11 2 13 8 1.4 9 100%  
  Prisons 
No 207 12 219 116 0 116 22 0 22 357 22% 
% 57.9 3 61 32 0 32 6 0 6 100%  
TOTAL 
No 811 90 901 484 53 537 209 19 228 1666 100% 
% 48 5.3 54 29 3 32 12 1 14 100%  
 
The total number of patients on methadone 
therapy (Table 1), refers to 10 cities, where allocated 
12 public health centers, with aim residence to have 
geographically accessible treatment and without 
financial burden for transport.  The number of 
inhabitants in Republic of Macedonia according to the 
State Statistical Office [34], is 2,058,539 inhabitants, 
distribution of women and men in the total population 
is equal, 49,9% of the population are women, 50,1 % 
are men [35]. From the analyzed data, 0.06% of the 
population has developed drug addiction and is 
included on OST with methadone. 
 
Table 2: Distribution of patients with developed drug addiction, who are receiving OST treatment in decentralized treatment 
centers in different cities in MKD. 
 Ohrid Veles Skopje Strumica Bitola Tetovo Kavadarci Gevgelija Kumanovo Shtip 
No of OST 
patients 
 TOTAL No 115 46 483 73 92 94 37 61 112 
67 
5 
No of 
females 
(from all 
OST 
patients) 
  14 6 61 11 7 8 2 8 14 
 % of the 
population 
with 
developed 
drug 
addiction 
 
            % 
 
0.2% 
 
0.08% 
 
0.1% 
 
0.1% 
 
0.09% 
 
0.1% 
 
0.09% 
 
0,26% 
 
0.1% 
 
0.1% 
 
From the data analysis it can be concluded 
that the number of OST patients is 0.1% of the total 
population in each of the 10 cities analyzed, except in 
Ohrid, where it is 0.2% and Gevgelija with 0.26% of 
the population. Both cities are attractive tourist 
locations close to the border; the frequency of people 
is very high, which may be one of the reasons for 
presence of people with developed opiate addiction, 
currently in treatment. At the same time it can be 
concluded that in 10 of 12 cities predominant number 
of OST patients are with age 20-34 years, except in 
Skopje and Ohrid. This information is worrying and it 
is a clear signal of the need to strengthen preventive 
measures and activities in MKD.  
All OST patients on MMT in prison (Table 1) 
are from three prisons: pretrial prison “Skopje” were 
190 (65%) OST patients (Total No was 290 
prisoners); in prison “Idrizovo” Skopje were 139 (11%) 
(Total number was 1,306 prisoners) and 38 (56%) in 
Prison Bitola (total number was 69 prisoners). Other 
patients (prisoners) within country are receiving MMT 
from community treatment centers and are presented 
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in total number of concerning center. Programs 
arranged in MKD, transfers community treatment OST 
patients, in consultation with the patient, on treatment 
with Methadone while he is in prison, with equal 
health attention like in community. Those programs 
also can ensure a smooth transition between prison 
and the community, after the imprisonment. In MKD 
there are 3 MMT centers in prisons: in pre-trial prisons 
in Skopje, prison “Skopje”; in regular prison “Idrizovo” 
and 38 in Prison Bitola. Other patients (prisoners) 
within country are receiving MMT from community 
treatment centers, total number is 60.Total number of 
prisoners in OST was 427. 
Table 3: Distribution of OST patients on MMT by ethnicity. 
Ethnicity Public centers Private centers Prisons TOTAL 
Macedonian No 812 126 180 1118 
% 73 11 16 70% 
Albanian No 279 7 117 403 
% 69 27 29 24% 
Roma No 33 3 60 96 
% 34 3 63 6% 
Others No 40 5 10 61 
% 75 8 16 0.4% 
TOTAL No 1164 141 367 1671 
% 70 8,4 22 100% 
 
With reflection of the distribution by ethnicity 
in all treatment facilities with MMT, there are 66.6% 
Macedonians, 24% Albanians, 6% Roma and 3.6% 
Others. 
 
Table 4: Patients on OST treatment with Buprenorphine 
maintenance in MKD. 
  Ethnicity 20-34 35-40 41-55 TO-TAL 
 M F Total M F Total M F Total 
Macedonian No 71 17 88 34 0 34 14 0 14 136 
% 52 12.5 65 25 0 25 10 0 10 73 
Albanian No 30 0 30 13 0 13 4 0 4 47 
25 
% 64 0 64 28 0 28 8.5 0 8.5 
Roma No 2 0 2 1 0 1 0 0 0 3 
% 67 0 67 33 0 33 0 0 0 1.6 
TOTAL No 103 17 120 14 0 48 18 0 18 186 
100% % 55 9 65 8 0 26 10 0 10 
 
In Macedonia, Buprenorphine is OST which is 
still exclusively applied in the University Clinic of 
Toxicology, on the tertiary health care level.  
Distribution by ethnicity in treatment facility 
with Buprenorphine, there are 73% Macedonians, 
25% Albanians, 2% Roma. 
Total number of OST patients in all available 
opioid substitution treatment facilities is 1,857, 10% 
are on Buprenorphine and 90% are on Methadone, 
from which 1,355 are in public OST (MMT and 
Buprenorphine). 
The ratio of male to female heroin clients is 
9:1; 162 are female (9%); 10% are on buprenorphin in 
comparison with 90% on methadone; 107(66%) are in 
treatment in the age group 20-34; 130(80%) are in 
public MMT.  From all OST patients, 54% patients on 
MMT and 65% OST patients on buprenorphine, are in 
age category group 20-34. It is evident that very 
young persons are heroin addicts, already on 
methadone treatment. It should be noted that injecting 
heroin in patients currently on drug treatment, starts 
between 14-22 years of age, and the average age of 
first heroin use is 18 years.  
Analysis of level of education, from the 
available data, showed that: a) without primary 
educations are total number of 101 patients(8.5%) 
distributed only in 5 cities (Skopje 49, Shtip 3, 
Kumanovo 8, Ohrid 17, Tetovo 24) b), with only 
primary education are 368 patients (32%); with high 
school (secondary education) are 683 patients (59%) 
Skopje 337 (29%), Strumica 47(4%), Shtip 33(3%), 
Bitola 50 (4%), Kumanovo 51 (4%), Ohrid 46 (4%), 
Tetovo11 (1%), Kavadarci 25 (2%), Veles 41 (3.5%), 
Gevgelija 45 (4%) and with higher education 11(1%). 
Living status data analysis of 1,314 OST 
patients (except OST patients from 3 prisons): living 
alone 57 (4.3%); with family 854 (65%); with partner 
326 (24.8%); with friends 13 (1%); 4 (0.3%) lives in an 
institution (not detention); in Prison 60 (4.6%). 83% 
(1090) of the patients have permanent residence. 
Drug patients with children in public OST: 487 patients 
(36%) have children; living with their children, 337 
patients (69%); not living with their children, 150 
patients (31%); no of patients who don’t have children, 
868 patients (58.3%). Labor status of patients on OST 
in public health institutions: part time job have 188 
(14%); 157 (12%), permanent employment; 10 (1%) 
students, not employed are 860 (63.4%), receives of 
social support, 141 (10%). 
 
Use of benzodiazepines (BZD) as secondary 
drugs 
   All public MMT centers recording BZD use, 
except one MMT center in Skopje and one are 
collecting medical data for BZD partially. Analyze in 
public MMT facilities refers to 831 patients, of which 
608 use BZD (73%). 
 
Table 5: Patients on OST treatment with diagnosed BZD use (ICD- 10, F13). 
 
20-34 35-40 41-55 TOTAL 
Total No OST 
patients 
M F Total M F Total M F Total   
  PUBLIC OST 
    
No 289 22 311 205 13 218 72 7 79 608 831 
% 47 4 51 34 2 36 12 1 13 100 73 
  PRIVATE OST 
No 76 11 87 13 3 16 7 2 9 113 141 
% 67 10 77 11.5 3 14 6 1.7 8 100 80 
TOTAL 
No 365 33 398 218 16 234 79 9 88 720 972 
% 51 4.5 55 30 2 32.5 11 1 12 74  
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`Analysis determines that: a) there is difference 
among BZD use and town of living; b) there is 
difference in BZD use and distribution by gender and 
age: 41% (398) of the patients are in the age group 
20-34; c) there is differences between the gender: 
Male are predominant with 662 patients (92%) in 
comparison Female are 58 (8%). 
 
Comparison of Macedonian data with data 
from 10 EU countries (Austria, Denmark, 
France, Germany, Greece, Italy, Norway, 
Portugal, Sweden, UK 
In EU 4:1 is the ratio of male to female heroin 
clients [36]. In Macedonia (MKD) the ratio of male to 
female heroin clients is 9:1.  
 
Table 6: Distribution of patients with diagnosed BZD use, who are receiving OST treatment in decentralized treatment centers in 
different cities in MKD. 
 Ohrid Veles Skopje Strumica Bitola Tetovo Kavadarci Gevgelija Kumanovo 
61 
 No of patients using BZD 
No 107 42 163 58 59 54 19 34 
% 93% 91% 81% 79% 64% 69% 56% 56% 53% 
 Total No of OST patients No 115 46 201 73 92 94 37 61 53 
 
Study in Israel has shown that females are 
more likely to enter MMT at a younger age than 
males, with more than double percentage of total 
female admissions occurring in the 18–30 age groups 
[37]. It is the similar situation in MKD where 1.6 % of 
female patients are in treatment in the age group 20-
34. In Macedonia male patients are 89 % from all 
patients, while in analysis carried out in ten EU 
countries (with The European Quality Audit of Opioid 
Treatment (EQUATOR [38], designed to provide an 
overview of the current state of opioid treatment 
provision in Europe) found 74.6% male patients. This 
distribution was also seen in individual countries and 
consistently are more men patients (range 66–82%) 
[39], 79% male opioid-dependent patients observed 
by the EMCDDA (data from countries taking part in 
EQUATOR) [40], 84% of OST patients in the 
PROTEUS study in Spain [41], 73% of OST in the 
DTORS study in the UK [42] and 68% male patients in 
the German PREMOS study [43].  The average age of 
patients across Europe was 36.5 years, ranging from 
an average of 31.9 years in Austria to 43.8 years in 
Denmark [44]. In the same way, the mean age of 
patients entering treatment for opioid dependence in 
the EMCDDA dataset [45] was 34.1 years; the mean 
age reported in the German COBRA [46] study 34.8 
years and in the PREMOS [47] study 35 years; 
PROTEUS [48] study in Spain, reported mean age 39 
years. In the UK DTORS study [49], patient on OST 
were aged between 25 and 44 years (45% were 25–
34 years; 27% were 35–44 years, 7% were ≥45 
years). Among Macedonian OST patient treated in 
public health facilities in 2012, data for age distribution 
is similar with findings of UK study with 52% patients 
in age category group 20-34; 33% in age group 41-55; 
and 16% between 41-55 years, which is evident that 
very young persons are heroin addicts already on 
methadone treatment. 
It should be noted that injecting heroin in 
patients currently on treatment of drug addiction in 
2012, in the Republic of Macedonia is between 14-22 
years of age. The mean age at first heroin use in EU 
[50] is 22 years and in comparison, in Macedonia is 
18 years.  
 
Discussions  
Treatment network of drug addiction in MKD 
is quite developed. However, it is necessary to further 
build the capacities and to increase the quality of 
medical care that will increase the availability, 
accessibility, diversification in terms of sensitivity to 
cultural differences, gender, age, ethnicity, as well as 
possibilities of treatment of different types of 
psychoactive substances not only heroin users but 
also cocaine, marijuana and users of new 
psychoactive substances, synthetic drugs etc. 
Methadone was introduced in MKD in 1992 
for opioids substitution treatment OST (MMT). 
Buprenorphine, introduced in 2009, is used for 
detoxification and substitution treatment. Nearly 1,250 
drug users are involved in a program for methadone 
maintenance therapy and receive daily or weekly 
substance.
 
Government of the Republic of Macedonia 
adopts the program each year for health care 
(covering all expenses for OST) for people with 
diseases of addiction. In the framework of the 
program for Building a Coordinative Response to 
HIV/AIDS Prevention in the country (supported by the 
Global Fund), the Ministry of Health opened 12 
services for treatment and harm reduction of drug 
abuse, with methadone maintenance treatment, in 10 
cities in MKD, as well as 3 programs in the prisons. A 
barrier to treatment entry like waiting lists for patients 
on methadone substitution program is not an issue in 
MKD. But, apparent problem is accumulation of big 
number of patients per centre especially in the city of 
Skopje. This could be overcome with expand of 
treatment access in different municipalities within the 
capital city Skopje, which besides the improvement in 
quality of health care, will be of benefit for the patients 
to reduce transport costs. In MKD, General population 
survey (GPS) is not performed yet, due to the lack of 
financial resources. Most recent scientific estimates 
which derived from the multiplier methods (RDS 
study) and Delphi estimate, suggests that the average 
number of Injecting drug users (IDUs) in Skopje is 
2,950 [51]. This study indicated that if the IDUs 
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number in Skopje is 2,950, than the extrapolation of 
this estimate to the national level will give the total 
estimated number of 10,200 IDUs (95%CI = 7450 –
14150; rounded to nearest fifty) in Macedonia. 
However, extrapolation of results from Skopje to other 
smaller cities in MKD and methodology for this studies 
should be taken with caution because it have run into 
divided expert opinions, especially the experts from 
EU countries (key experts within the REITOX network 
of the EMCDDA, for the Indicator problematic drug 
users (PDUs). 
Gender is an important variable to consider in 
substance abuse treatment research. Female 
substance abusers experience a number of barriers to 
receiving treatment, including child care 
responsibilities, stigmatization, and religion obstacles. 
Female substance abusers are more vulnerable than 
male to some of the physiological effects of 
substance, also substance abuse among females is 
rooted more often in psychosocial problems and 
traumatic life events and these important gender 
differences suggest the need for specialized treatment 
programming for women [52]. 
With regards to level of education, 
comparison between MKD data and data presented in 
studies, showed that MKD patients in OST with 37% 
of patients, with no high school is near data from 
Sweden (35.5%) and UK (39.5), lower than EU 
average (42.3), Denmark (56.3%), Germany (59%), 
Italy (54%). With 62% of high school education degree 
among MKD patients in OST is equal with findings in 
Spain (62.4%); higher than EU average (30.9%). With 
1% of Graduate education, MKD is identical with UK 
(1.2%), which is bigger than EU average (0.3%). 
Demographic data are important for un-
derstanding the real-life circumstances and potential 
clinical needs of the target population for OST, 
because the new focus on ‘recovery’ places great 
emphasis on helping patients not only to reduce their 
drug use but also to build and exploit their own social, 
physical, financial and cultural resources to sustain 
their recovery and reintegrate into society [53]. It is 
therefore useful to understand the educational, 
marital, employment status and other demographic 
characteristics of those who are in or out of treatment 
in order to assess their ability to achieve these goals 
[54]. 
It has been estimated that up to one third of 
all heroin dependent people pass through a 
correctional facility each year [55]. The chronic nature 
of untreated heroin dependence means that 
imprisonment is usually a repeated experience; in 
studies in the US and France, half of heroin users 
released from prison were returnees in prison within 
six months [56-57]. 
Polydrug use is predominant among drug 
users mixing of substances is carried out to reduce 
the unwanted effects or to enhance the desired ones 
[58-61]. The substances detected most often were 
combinations of morphine, benzodiazepine, 
methadone, stimulants. In terms of poly drug use, the 
use of benzodiazepines ranges between 11 % and 70 
% among substitution treatment clients [62]. 
Benzodiazepines are widely used by heroin 
dependent individuals and by patients in opioid 
substitution treatment [63]. This high level of use may 
be in response to the high incidence of psychiatric co-
morbidity in this population [64]. 
Benzodiazepine use by MMT patients is 
associated with a more complex clinical picture and 
may negatively influence treatment outcomes [65]. 
Although several studies indicate that rates of 
nonmedical prescription drug use are higher among 
women than men, particularly for narcotic analgesics 
and tranquilizers [66], other studies report equivalent 
or higher rates among men [67]. 
In this moment it is difficult to recognize single 
medical opiate users, but in very near future with 
implementation of electronic health card, with 
recording of health status for single patient it will be 
very easy to obtain health statistics, for scientific 
purposes and with respect of personal’s confidential 
information. For the purpose of this paper we can look 
through data for use of opiates and opioids for 
medical purposes, expressed as grams of active 
component controlled by Conventions for drug control 
of the United Nations (UN 1961, 1971, 1988). MKD is 
a country that cultivate poppy (Papaver somniferum) 
and performs extraction of alkaloids for medical 
purposes, i.e. providing primary production of opiates 
(natural derivatives of opium). In terms of synthetic 
opioids MKD performs secondary production. From 
produced amounts of opiates and opioids parts are 
exported to other countries and part is for domestic 
medical purposes. The whole process is approved by 
the MKD Ministry of Health and International Board for 
Drug Control of the United Nations. Approved MKD 
data for opiates are part of INCB annual reports [68]. 
Annual estimated needs [69] for substitution treatment 
in MKD for drug addiction is 38kg of 400 g methadone 
for 1200 patients and buprenorfin for 210 patients 1 kg 
95 g. 
Concerning medical opiates, data from Form 
C report for 2012 [70] are: from the produced 1,343 kg 
and 249 g Codeine, only 30 g were consumed like 
Codeine, other quantities were utilized for the 
manufacture of Schedule III preparations; from the 
produced 5 kg and 614 g Morphine Hydrochloride and 
Sulphat, only 30 g were consumed in MKD, other 
quantities were exported for medical purposes; 87 kg 
and 302 g of Pholcodine were utilized for manufacture 
of Schedule III preparations. With regards to opioids 
MKD patients in 2012 consumed 17 mg Fentanyl and 
7 mg Remifentanyl. From produced 180 kg 
Methadone, only 25 kg were used in MKD, other 
quantities were exported with approval from 
Macedonian Ministry of Health and UN INCB, to other 
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countries, for medical purposes. 
In Macedonia different treatment options for 
opioid dependent persons are functioning. Persons in 
prisons receive the same level of health care like in 
the community. Demographic profiles appeared 
relatively consistent across the country, with 
differences in mean age of patients in treatment, 
namely while in capital city Skopje predominant age 
group is 35-40, in rest of Macedonian towns patients 
are on the age 20-34. It should be noted that in private 
OST psychiatric clinics, no meter that all are placed in 
capital city Skopje, patients are with age 20-34.  The 
same situation is among prison patients, 62% are on 
the age 20-34. It is important to strengthen drugs 
preventive measures, to raise awareness and level of 
information. Ratio female: male patients is bigger that 
EU average and it should be further explored what are 
the reasons. There is correlation between low level of 
education and start of heroin abuse. Benzodiazepine 
use among MMT patients is common. This very 
important and comprehensive analyze of persons with 
drug addiction can lead to successful prevention and 
treatment responses. Although treatment network of 
drug addiction is quite developed, perceived need for 
further capacity building and increase the quality of 
medical care implies increasing the availability, 
diversification in terms of sensitivity to cultural 
differences, gender, age, ethnicity, as well as the 
treatment of dependence of different types of 
psychoactive substances. 
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